Human leukocyte antigen (HLA)-based immunotherapeutics, such as tebentafusp-tebn and afamitresgene autoleucel, have expanded the treatment options for HLA-A*02-positive patients with rare solid tumors such as uveal melanoma, synovial sarcoma, and myxoid liposarcoma...Last, we emphasize the urgent need for further research to better understand HLA allotype heterogeneity and its influence on tumor immunopeptidome-driven immune responses. We anticipate that these strategies will accelerate the development and implementation of both personalized and broad-spectrum HLA-based immunotherapies, and will ultimately improve cancer treatment across genetically heterogeneous patient populations worldwide.

2 months ago

Review • Journal

HLA-A (Major Histocompatibility Complex, Class I, A)

HLA-A*02 positive

Kimmtrak (tebentafusp-tebn) • Tecelra (afamitresgene autoleucel)

2ms

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer (clinicaltrials.gov)

P1, N=22, Active, not recruiting, Massachusetts General Hospital | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Jun 2025 --> Dec 2026

2 months ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative • HLA-A*02 positive

Imfinzi (durvalumab) • Hiltonol (poly-ICLC) • PVX-410

4ms

HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer. (PubMed, J Immunother Cancer)

These results provide the preclinical rationale for developing T-cell-based approaches against HERV-K-derived epitopes in ovarian cancer.

4 months ago

Journal • Tumor mutational burden • IO biomarker

TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)

HLA-A*02 positive

7ms

Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from LDHC in lung adenocarcinoma. (PubMed, Front Immunol)

P6 (LDHC172-180, YLIGEKLGV) elicited the strongest IFN-γ-secreting cytotoxic T lymphocyte (CTL) response and exhibited potent cytotoxicity against HLA-A2-positive cells with high LDHC expression. LDHC may serve as a targetable biomarker for peptide-based immunotherapy of LUAD.

7 months ago

Journal • IO biomarker

IFNG (Interferon, gamma)

HLA-A*02 positive

10ms

ALLOHA: A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation (clinicaltrials.gov)

P1, N=63, Recruiting, TScan Therapeutics, Inc. | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Dec 2025

10 months ago

Trial completion date • Trial primary completion date

HLA-A (Major Histocompatibility Complex, Class I, A)

HLA-A*02 • HLA-A*02 positive

melphalan • TSC-100 • TSC-101

over4years

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer (clinicaltrials.gov)

P1/2, N=11, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Dec 2020 --> Dec 2021

over 4 years ago

Clinical • Trial primary completion date

HLA-A (Major Histocompatibility Complex, Class I, A)

HLA-A2 positive • HLA-A*02 positive

DPX-E7

over4years

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) (clinicaltrials.gov)

P1, N=14, Active, not recruiting, Nicholas Butowski | Recruiting --> Active, not recruiting | N=30 --> 14

over 4 years ago

Clinical • Enrollment closed • Enrollment change

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)

HLA-A2 positive • HLA-A*02 positive

varlilumab (CDX 1127) • Hiltonol (poly-ICLC) • IMA950